CN101448497B - 包含硝唑尼特、替唑尼特、或其混合物的组合物在制备治疗丙型肝炎药物中的应用 - Google Patents

包含硝唑尼特、替唑尼特、或其混合物的组合物在制备治疗丙型肝炎药物中的应用 Download PDF

Info

Publication number
CN101448497B
CN101448497B CN2007800077942A CN200780007794A CN101448497B CN 101448497 B CN101448497 B CN 101448497B CN 2007800077942 A CN2007800077942 A CN 2007800077942A CN 200780007794 A CN200780007794 A CN 200780007794A CN 101448497 B CN101448497 B CN 101448497B
Authority
CN
China
Prior art keywords
interferon
patient
treatment
nitazoxanide
hepatitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2007800077942A
Other languages
English (en)
Chinese (zh)
Other versions
CN101448497A (zh
Inventor
J·-F·罗西诺尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Romark Laboratories LC
Original Assignee
Romark Laboratories LC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Romark Laboratories LC filed Critical Romark Laboratories LC
Publication of CN101448497A publication Critical patent/CN101448497A/zh
Application granted granted Critical
Publication of CN101448497B publication Critical patent/CN101448497B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicinal Preparation (AREA)
CN2007800077942A 2006-01-09 2007-01-09 包含硝唑尼特、替唑尼特、或其混合物的组合物在制备治疗丙型肝炎药物中的应用 Expired - Fee Related CN101448497B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75703606P 2006-01-09 2006-01-09
US60/757,036 2006-01-09
PCT/US2007/000574 WO2007081974A2 (en) 2006-01-09 2007-01-09 Viral hepatitis treatment

Publications (2)

Publication Number Publication Date
CN101448497A CN101448497A (zh) 2009-06-03
CN101448497B true CN101448497B (zh) 2013-07-10

Family

ID=38257004

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2007800077942A Expired - Fee Related CN101448497B (zh) 2006-01-09 2007-01-09 包含硝唑尼特、替唑尼特、或其混合物的组合物在制备治疗丙型肝炎药物中的应用

Country Status (17)

Country Link
US (3) US8633230B2 (enExample)
EP (1) EP1976516B9 (enExample)
JP (2) JP5185826B2 (enExample)
CN (1) CN101448497B (enExample)
AP (1) AP2907A (enExample)
AU (1) AU2007204963B2 (enExample)
BR (1) BRPI0706379A2 (enExample)
CA (1) CA2636527C (enExample)
DK (1) DK1976516T3 (enExample)
EA (1) EA015560B1 (enExample)
ES (1) ES2422556T3 (enExample)
IL (1) IL192548A (enExample)
MX (1) MX2008008723A (enExample)
NZ (1) NZ569507A (enExample)
UA (1) UA100840C2 (enExample)
WO (1) WO2007081974A2 (enExample)
ZA (1) ZA200806310B (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006110814A2 (en) * 2005-04-12 2006-10-19 Romark Laboratories, L.C. Methods for treating diseases through inhibition the function of molecular chaperones such as protein disulfide isomerases, pharmaceutical compositions comprising them, and screening methods for identifying therapeutic agents
CN101448497B (zh) * 2006-01-09 2013-07-10 罗马克实验室有限公司 包含硝唑尼特、替唑尼特、或其混合物的组合物在制备治疗丙型肝炎药物中的应用
BRPI0814363A2 (pt) * 2007-07-25 2015-01-27 Biolex Therapeutics Inc Produtos fármacos de interferon de liberação controlada e tratamento de infecção por hcv usando os mesmos
LT2395840T (lt) * 2009-02-13 2020-07-10 Romark Laboratories, L.C. Nitazoksanido kontroliuojamo atpalaidavimo farmacinės kompozicijos
US8835644B2 (en) 2009-03-20 2014-09-16 University Of Virginia Patent Foundation Broad spectrum benzothiophene-nitrothiazolide and other antimicrobials
KR101760956B1 (ko) * 2009-05-12 2017-07-24 로마크 레버러토리즈, 엘.씨. 할로알킬 헤테로아릴 벤즈아미드 화합물
KR20180032689A (ko) 2009-06-26 2018-03-30 로마크 레버러토리즈, 엘.씨. 인플루엔자를 치료하기 위한 화합물 및 방법
EP2632460B1 (en) 2010-09-20 2018-02-28 University of Virginia Patent Foundation Thiophene derivatives for use in the treatment of tuberculosis
MX2013013115A (es) 2011-05-16 2014-02-27 Romark Lab Lc Uso de compuestos de tiazolida para la prevencion y tratamiento de enfermedades virales, cancer y enfermedades causadas por infecciones intracelulares.
CN102805747B (zh) * 2011-06-01 2013-09-18 漳州片仔癀药业股份有限公司 2-(4-吗啉苯胺)-6-环己基氨基嘌呤及其药学上可接受的盐在制药中的用途
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
AU2013201406B2 (en) 2011-10-21 2014-10-02 Abbvie Ireland Unlimited Company Methods for treating HCV
EP2583680A3 (en) 2011-10-21 2013-06-12 Abbvie Inc. Mono (PSI-7977) or combination treatment of DAAs for use in treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
WO2013110975A1 (es) 2012-01-27 2013-08-01 Siegfried Rhein S.A. De C.V. Composición de nitazoxanida mejorada y proceso para prepararla
KR20170081228A (ko) 2014-11-11 2017-07-11 로마크 레버러토리즈, 엘.씨. 티족사나이드, 그의 유사체 또는 염의 전구 약물을 이용한 치료 조성물 및 방법
US20180098972A1 (en) 2015-01-26 2018-04-12 Children's Medical Center Corporation Treatment of infectious diseases
HUE050601T2 (hu) 2016-03-31 2020-12-28 Romark Laboratories Lc Tiazolidvegyületek vírusfertõzések kezelésére
PH12018502142B1 (en) * 2016-04-11 2023-08-11 Genfit Methods of treatment for cholestatic and fibrotic diseases
US20170290814A1 (en) * 2016-04-11 2017-10-12 Genfit Methods of treatment of cholestasis and fibrosis
WO2017189978A1 (en) 2016-04-28 2017-11-02 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
EP3573957B1 (en) 2017-01-24 2023-04-26 Rivara, Mirko Compositions and methods for blocking sodium channels
KR102537043B1 (ko) * 2017-01-27 2023-05-25 장피트 조합 치료요법용 약학 조성물
EP3595656A1 (en) * 2017-03-13 2020-01-22 Genfit Pharmaceutical compositions for combination therapy
US11173149B2 (en) 2017-04-18 2021-11-16 Romark Laboratories L.C. Inhibition of protein disulfide-isomerase A3
AU2018368611B2 (en) * 2017-11-17 2023-12-14 KÖSTER, Hubert (2-((5-nitro-1,3-thiazol-2-yl)carbamoyl)phenyl)ethanoate for use in lymphangioleiomyomatosis and other diseases
CN109364067B (zh) * 2018-11-17 2020-07-28 王海玲 一种化合物在制备提高血脑屏障通透性药物中的用途
JP2022527840A (ja) 2019-04-09 2022-06-06 ジェンフィット 免疫疾患又は炎症を治療するためのニタゾキサニド及びエラフィブラノールの組合せ
WO2021016543A1 (en) * 2019-07-25 2021-01-28 Romark Laboratories L.C. Antiviral combinations of thiazolide compounds
CN111012788B (zh) * 2019-12-12 2021-01-15 武汉职业技术学院 硝唑尼特和替唑尼特在制备抗猪繁殖与呼吸综合征病毒药物中的应用
EP4182304A1 (en) 2020-07-20 2023-05-24 Romark Laboratories, L.C. Crystalline salts of tizoxanide and 2-hydroxy-n-(5-chloro-1,3-thiazol-2-yl)benzamide (rm-4848) with ethanolamine, morpholine, propanolamine, piperazine and n-methylpiperazine
CN116367892A (zh) 2020-08-24 2023-06-30 罗马克实验室有限公司 噻唑化物抗冠状病毒的用途
CN114259492A (zh) * 2021-12-21 2022-04-01 中以海德人工智能药物研发股份有限公司 硝唑尼特在治疗乙肝中的应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1437800A (en) * 1973-08-08 1976-06-03 Phavic Sprl Derivatives of 2-benzamido-5-nitro-thiazoles
GB1440212A (en) * 1973-08-29 1976-06-23 Phavic Sprl Derivatives of 2-phenoxyacetamido-5-nitrothiazoles
US4315018A (en) * 1978-12-07 1982-02-09 Rossignol Jean F Specific parasiticidal use of 2-benzamido-5-nitro-thiazole derivatives
US5578621A (en) * 1994-09-08 1996-11-26 Romark Lab Lc Benzamide derivatives
CN1072654C (zh) * 1994-04-13 2001-10-10 让-弗兰克伊斯·罗西格诺尔 苯甲酰胺衍生物,含所述衍生物的组合物及它们的用途
US5387598A (en) * 1994-04-13 1995-02-07 Rossignol; Jean-Francois Composition and galenic formulation suitable for combatting affections of the lower abdomen
US5965590A (en) * 1994-09-08 1999-10-12 Romark Lab Lc Method for treatment of opportunistic infections with pharmaceutical compositions of tizoxanide and nitazoxanide
MX9604483A (es) * 1994-09-08 1998-02-28 Jean-Francois Rossignol Derivados de benzamida, composiciones que contienen dicho derivado y uso de las mismas.
US5859038A (en) * 1994-09-08 1999-01-12 Romark Laboratories, L.C. Method for treatment of helicobacter pylori infections
US5856348A (en) * 1994-09-08 1999-01-05 Romark Laboratories, L.C. Method for treatment of trematodes with pharmaceutical compositions of tizoxanide and nitazoxanide
US5968961A (en) * 1997-05-07 1999-10-19 Romark Laboratories, L.C. Pharmaceutical compositions of tizoxanide and nitazoxanide
US6576636B2 (en) * 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
TR199902733T2 (xx) * 1997-05-07 2000-03-21 Romark Laboratories, L.C. Tizoksanit ve nitazoksanitten olu�an farmas�tik kompozisyonlar.
US5935591A (en) * 1998-01-15 1999-08-10 Romark Laboratories, L.C. Method for treatment of equine protozoal myeloencephalitis with thiazolides
CN1230198C (zh) * 1998-05-15 2005-12-07 先灵公司 给首次接受抗病毒疗法的G慢性丙型肝炎感染患者施用包括利巴韦林和α干扰素的联合疗法
US5925622A (en) * 1998-07-13 1999-07-20 Romark Laboratories, L.C. Synthesis of aryl glucuronide of 2-hydroxy-N- (5-nitro-2-thiazolyl) benzamide, and pharmaceutical compositions comprising same
US6180136B1 (en) * 1998-11-10 2001-01-30 Idexx Laboratories, Inc. Phospholipid-coated microcrystals for the sustained release of pharmacologically active compounds and methods of their manufacture and use
US6340696B1 (en) * 1999-03-31 2002-01-22 The Procter & Gamble Company Viral treatment
US7125568B2 (en) * 2001-08-23 2006-10-24 Sung Michael T Lipophilic drug compositions
CN100438868C (zh) 2002-10-29 2008-12-03 科学与工业研究委员会 天然来源的葡萄糖苷酶抑制剂
US7081260B2 (en) * 2002-10-29 2006-07-25 Council Of Scientific And Industrial Research α-Glucosidase inhibitors from a natural source
CA2520853A1 (en) * 2003-03-28 2005-03-31 Centocor, Inc. Anti-amyloid antibodies, compositions, methods and uses
US7410979B2 (en) 2003-11-19 2008-08-12 Rigel Pharmaceuticals, Inc. Synergistically effective combinations of dihaloacetamide compounds and interferon or ribavirin against HCV infections
UA90864C2 (en) * 2004-09-09 2010-06-10 Ромарк Лебораториз, Л.К. Halogenated benzamide derivatives
US20060194853A1 (en) * 2004-10-08 2006-08-31 Rossignol Jean F Alkyl benzamides
WO2006110814A2 (en) 2005-04-12 2006-10-19 Romark Laboratories, L.C. Methods for treating diseases through inhibition the function of molecular chaperones such as protein disulfide isomerases, pharmaceutical compositions comprising them, and screening methods for identifying therapeutic agents
CN101448497B (zh) 2006-01-09 2013-07-10 罗马克实验室有限公司 包含硝唑尼特、替唑尼特、或其混合物的组合物在制备治疗丙型肝炎药物中的应用
LT2395840T (lt) * 2009-02-13 2020-07-10 Romark Laboratories, L.C. Nitazoksanido kontroliuojamo atpalaidavimo farmacinės kompozicijos

Also Published As

Publication number Publication date
HK1123733A1 (en) 2009-06-26
WO2007081974A3 (en) 2008-01-17
JP2010070566A (ja) 2010-04-02
WO2007081974A2 (en) 2007-07-19
AU2007204963B2 (en) 2012-09-27
UA100840C2 (ru) 2013-02-11
ES2422556T3 (es) 2013-09-12
DK1976516T3 (da) 2013-07-15
EP1976516A2 (en) 2008-10-08
BRPI0706379A2 (pt) 2011-03-22
NZ569507A (en) 2011-11-25
US20070167504A1 (en) 2007-07-19
AP2008004550A0 (en) 2008-08-31
USRE47404E1 (en) 2019-05-28
IL192548A0 (en) 2009-02-11
EA200870164A1 (ru) 2008-12-30
CA2636527A1 (en) 2007-07-19
EP1976516B1 (en) 2013-04-24
AU2007204963A1 (en) 2007-07-19
JP2009522371A (ja) 2009-06-11
US20140112888A1 (en) 2014-04-24
EP1976516B9 (en) 2013-10-30
US9107913B2 (en) 2015-08-18
CN101448497A (zh) 2009-06-03
JP5185826B2 (ja) 2013-04-17
CA2636527C (en) 2016-05-17
US8633230B2 (en) 2014-01-21
AP2907A (en) 2014-05-31
ZA200806310B (en) 2009-12-30
MX2008008723A (es) 2008-09-26
IL192548A (en) 2015-08-31
EP1976516A4 (en) 2009-11-11
EA015560B1 (ru) 2011-08-30

Similar Documents

Publication Publication Date Title
CN101448497B (zh) 包含硝唑尼特、替唑尼特、或其混合物的组合物在制备治疗丙型肝炎药物中的应用
JP2009522371A5 (enExample)
CN102026641A (zh) 并用或组合dpp-iv抑制剂和其它糖尿病治疗药的药品
CN102105153A (zh) 使用sglt2抑制剂和含其组合物治疗高尿酸血症的方法
JP2008515816A (ja) カスタノスペルミンを含有する、併用抗ウイルス組成物およびその使用方法
RU2448726C2 (ru) Содержащий g-csf агент для предупреждения и лечения диабетической периферической нейропатии
SI21079A (sl) Formulacija, ki povečuje mobilizacijo
CN1655820A (zh) Pde5抑制剂与ace抑制剂的药物组合
WO2013116592A1 (en) Once daily treatment of hepatitis c with ribavirin and taribavirin
CN115671105B (zh) Ly2922470在制备预防或治疗肾脏疾病药物中的应用
CN118178405A (zh) 甲苯咪唑在制备预防或治疗肝纤维化药物中的应用
CN101204578A (zh) 一种具有调节免疫、抗组织损伤及再生修复作用的胸腺素复合制剂
JPH11269076A (ja) 抗線維化剤
CN115429871B (zh) 司美格鲁肽新用途
CN119868383B (zh) 桑皮苷a在制备预防和治疗肺纤维化疾病的药物中的应用
WO2005027910A1 (en) Method of treating mixed lineage leukemia gene-rearranged acute lymphoblastic leukemias
HK1123733B (en) Viral hepatitis treatment
US7846901B2 (en) Method for inhibiting or treating intestinal damage caused by radiotherapy or chemotherapy comprising administering substance-P
Hwang et al. Dose-dependent glucosuria of DWP16001, a novel selective SGLT-2 inhibitor, in healthy subjects
CN118593509A (zh) 非戈替尼作为抗三阴性乳腺癌药物bbdi的增敏剂的用途
JPH0262891A (ja) タンパク尿症改善剤
CN120381449A (zh) 化合物clt-28643在制备防治肝纤维化药物中的应用
CN121130057A (zh) 黑素细胞刺激素α-MSH在治疗肝癌中的应用
CN107569492A (zh) 氟维司群在制备治疗生长激素腺瘤的药物中的用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20130710

Termination date: 20220109

CF01 Termination of patent right due to non-payment of annual fee